Spotlight

UCL Enterprise Annual Review 2013/2014

Welcome to the third full year of the delivery phase of UCL’s enterprise strategy. As anticipated, our community continues to strive for excellence and that approach and commitment is clearly working. From working with corporations to assisting student entrepreneurs and spinning out research, We hope that you will enjoy reading about all our enterprise activities from across the university in this Annual Review for 2013/2014.

Professor Stephen Caddick
Vice-Provost (Enterprise and London)

Read the UCL Enterprise Annual Review



follow us on twitter


Professor Stephen Caddick

VICE-PROVOST (ENTERPRISE AND LONDON)

T: +44 (0)20 3108 5072
E: VPEnterprise@ucl.ac.uk

Stephen Caddick

UCL Enterprise is led by the Vice-Provost (Enterprise and London), Professor Stephen Caddick. The Office of the Vice-Provost (Enterprise) is responsible for delivering UCL’s Enterprise agenda with the greatest economic and societal impact. The Vice-Provosts are members of the Provost's senior management team.

“Enterprise is important to all universities, but resonates particularly with UCL. From our inception we were created as an enterprising institution, with a bold ambition to create a University dedicated to the greatest good for the greatest number. There are outstanding opportunities for us to work with all academic departments and divisions to help enrich the core academic mission of teaching and research and to identify innovative ways of engagement with the wider world. An enterprising community is one that is resourceful, creative, dynamic, and bold – characteristics that we recognise as part of the fabric of UCL.”
Professor Stephen Caddick, Vice-Provost (Enterprise and London)

Professor Stephen Caddick was appointed as Vice-Provost (Enterprise) in 2010. He joined UCL in 2003 as Vernon Professor of Organic Chemistry and Chemical Biology. He was the founding director of the Centre for Chemical Biology, and Head of the Department of Chemistry. He maintains an active academic research career, has many external roles and is co-founder of Thiologics, a spin-out company dedicated to developing new biological therapeutics.